Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07WCT
|
|||
| Former ID |
DIB011175
|
|||
| Drug Name |
SAR-100842
|
|||
| Synonyms |
LPA1/LPA3 antagonist (renal fibrosis), sanofi-aventis
Click to Show/Hide
|
|||
| Indication | Fibrosis [ICD-11: GA14-GC01; ICD-10: L90.5; ICD-9: 709.2] | Phase 2 | [1] | |
| Systemic sclerosis [ICD-11: 4A42; ICD-9: 710.1] | Phase 2 | [2] | ||
| Company |
Sanofi us
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H27NO5
|
|||
| Canonical SMILES |
CC1=CC(=CC=C1)CCOC2=C(C=CC(=C2)C(=O)NC3(CC4=CC=CC=C4C3)C(=O)O)OC
|
|||
| InChI |
1S/C27H27NO5/c1-18-6-5-7-19(14-18)12-13-33-24-15-20(10-11-23(24)32-2)25(29)28-27(26(30)31)16-21-8-3-4-9-22(21)17-27/h3-11,14-15H,12-13,16-17H2,1-2H3,(H,28,29)(H,30,31)
|
|||
| InChIKey |
SOJDTNUCCXWTMG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1195941-38-8
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lysophosphatidate-3 receptor (LPAR3) | Target Info | Modulator | [3] |
| Lysophosphatidic acid receptor 1 (LPAR1) | Target Info | Modulator | [3] | |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| PI3K-Akt signaling pathway | ||||
| Gap junction | ||||
| Pathways in cancer | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Pathway Interaction Database | LPA receptor mediated events | |||
| Reactome | G alpha (q) signalling events | |||
| G alpha (i) signalling events | ||||
| Lysosphingolipid and LPA receptors | ||||
| WikiPathways | Myometrial Relaxation and Contraction Pathways | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01651143) Proof of Biological Activity of SAR100842 in Systemic Sclerosis. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling. Biomol Ther (Seoul) 2015 January; 23(1): 1-11. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.